Celgene Corporation has announced that data from FIRST (MM-020/IFM 07-01) – an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant – have been published in the New England Journal of Medicine.

Initial findings, including that the trial had met its primary endpoint of progression free survival (PFS), were reported during the plenary session at the 55th American Society of Hematology annual meeting in December 2013.

READ FULL ARTICLE Curated publisher From Medical News Today